NewLink ax­es 100 staffers, shrinks pipeline in wake of a PhI­II de­ba­cle

A lit­tle more than two months af­ter NewLink Ge­net­ics $NLNK was slammed by the Phase III fail­ure of its pan­cre­at­ic can­cer vac­cine al­gen­pan­tu­cel-L, the Ames, Iowa-based com­pa­ny has slashed 100 staffers and cut some of its clin­i­cal work in a painful re­struc­tur­ing.

The cuts, an­nounced ahead of the mar­ket open­ing Fri­day, will see off any Hy­per­A­cute Cel­lu­lar Im­munother­a­py clin­i­cal tri­als that don’t in­clude a check­point drug. The biotech is al­so shrink­ing its man­u­fac­tur­ing op­er­a­tions as well as its fa­cil­i­ties, emp­ty­ing out of about half of its head­quar­ters.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER